Defibrotide: meta-analysis of COVID-19 studies

All studies   Exclusions   Mortality   ICU   Hospitalization   Recovery   RCTs   RCT mortality   Peer-reviewed   All outcomes  
0 0.5 1 1.5+ All studies -23% 1 150 Improvement, Studies, Patients Relative Risk Mortality -23% 1 150 ICU admission 0% 1 150 Hospitalization -18% 1 113 RCTs -23% 1 150 Late -23% 1 150 Defibrotide for COVID-19 c19early.org June 2026 Favorsdefibrotide Favorscontrol
0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Jara Rubio (DB RCT) -23% 1.23 [0.66-2.27] death 27/100 11/50 Improvement, RR [CI] Treatment Control Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.52 Late treatment -23% 1.23 [0.66-2.27] 27/100 11/50 23% higher risk All studies -23% 1.23 [0.66-2.27] 27/100 11/50 23% higher risk 1 defibrotide COVID-19 study c19early.org June 2026 Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.52 Effect extraction pre-specified(most serious outcome) Favors defibrotide Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Jara Rubio -23% 1.23 [0.66-2.27] death 27/100 11/50 Improvement, RR [CI] Treatment Control Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.52 Late treatment -23% 1.23 [0.66-2.27] 27/100 11/50 23% higher risk All studies -23% 1.23 [0.66-2.27] 27/100 11/50 23% higher risk 1 defibrotide COVID-19 study after exclusions c19early.org June 2026 Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.52 Effect extraction pre-specified(most serious outcome) Favors defibrotide Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Jara Rubio (DB RCT) -23% 1.23 [0.66-2.27] 27/100 11/50 Improvement, RR [CI] Treatment Control Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.52 Late treatment -23% 1.23 [0.66-2.27] 27/100 11/50 23% higher risk All studies -23% 1.23 [0.66-2.27] 27/100 11/50 23% higher risk 1 defibrotide COVID-19 mortality result c19early.org June 2026 Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.52 Favors defibrotide Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Jara Rubio (DB RCT) 0% 1.00 [0.81-1.24] 72/100 36/50 Improvement, RR [CI] Treatment Control Tau​2​ = 0.00, I​2​ = 0.0%, p = 1. Late treatment 0% 1.00 [0.81-1.24] 72/100 36/50 no change All studies 0% 1.00 [0.81-1.24] 72/100 36/50 no change 1 defibrotide COVID-19 ICU result c19early.org June 2026 Tau​2​ = 0.00, I​2​ = 0.0%, p = 1. Favors defibrotide Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Jara Rubio (DB RCT) -18% 1.18 [0.80-1.74] hosp. time 74 (n) 39 (n) Improvement, RR [CI] Treatment Control Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.41 Late treatment -18% 1.18 [0.80-1.74] 74 (n) 39 (n) 18% higher risk All studies -18% 1.18 [0.80-1.74] 74 (n) 39 (n) 18% higher risk 1 defibrotide COVID-19 hospitalization result c19early.org June 2026 Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.41 Favors defibrotide Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Jara Rubio (DB RCT) -33% 1.33 [0.95-1.88] recov. time 100 (n) 50 (n) Improvement, RR [CI] Treatment Control Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.1 Late treatment -33% 1.33 [0.95-1.88] 100 (n) 50 (n) 33% higher risk All studies -33% 1.33 [0.95-1.88] 100 (n) 50 (n) 33% higher risk 1 defibrotide COVID-19 recovery result c19early.org June 2026 Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.1 Favors defibrotide Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Jara Rubio (DB RCT) -23% 1.23 [0.66-2.27] death 27/100 11/50 Improvement, RR [CI] Treatment Control Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.52 Late treatment -23% 1.23 [0.66-2.27] 27/100 11/50 23% higher risk All studies -23% 1.23 [0.66-2.27] 27/100 11/50 23% higher risk 1 defibrotide COVID-19 Randomized Controlled Trial c19early.org June 2026 Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.52 Effect extraction pre-specified(most serious outcome) Favors defibrotide Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Jara Rubio (DB RCT) -23% 1.23 [0.66-2.27] 27/100 11/50 Improvement, RR [CI] Treatment Control Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.52 Late treatment -23% 1.23 [0.66-2.27] 27/100 11/50 23% higher risk All studies -23% 1.23 [0.66-2.27] 27/100 11/50 23% higher risk 1 defibrotide COVID-19 RCT mortality result c19early.org June 2026 Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.52 Favors defibrotide Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Jara Rubio (DB RCT) -23% 1.23 [0.66-2.27] death 27/100 11/50 Improvement, RR [CI] Treatment Control Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.52 Late treatment -23% 1.23 [0.66-2.27] 27/100 11/50 23% higher risk All studies -23% 1.23 [0.66-2.27] 27/100 11/50 23% higher risk 1 defibrotide COVID-19 peer reviewed studies c19early.org June 2026 Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.52 Effect extraction pre-specified(most serious outcome) Favors defibrotide Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Jara Rubio (DB RCT) -23% 1.23 [0.66-2.27] death 27/100 11/50 Improvement, RR [CI] Treatment Control Jara Rubio (DB RCT) -5% 1.05 [0.55-1.97] death 23/100 11/50 Jara Rubio (DB RCT) -200% 3.00 [0.70-12.9] progression 12/100 2/50 Jara Rubio (DB RCT) 0% 1.00 [0.81-1.24] ICU 72/100 36/50 Jara Rubio (DB RCT) -18% 1.18 [0.80-1.74] hosp. time 74 (n) 39 (n) Jara Rubio (DB RCT) -33% 1.33 [0.95-1.88] recov. time 100 (n) 50 (n) Jara Rubio (DB RCT) -33% 1.33 [0.37-4.81] misc. 8/100 3/50 Jara Rubio (DB RCT) 6% 0.94 [0.60-1.50] misc. 34/100 18/50 Defibrotide COVID-19 outcomes c19early.org June 2026 Favors defibrotide Favors control